SR

Shantha Raju

Stealth Mode Biotech, CHO Plus, University of Mysore, Venn Therapeutics

ORCID iD 0000-0002-6698-2508
Follow

About

Dr. T. Shantha Raju (Raju) is a biotech executive and has more than 25 years of biotech industry experience. He is currently working as an executive for a stealth mode biotech company. Prior to this he worked at CHO Plus, Venn Therapeutics and also as a Senior Director at Medimmune. Prior to Medimmune Dr. Raju was a Scientific Director at Janssen R&D of Janssen Pharmaceutical Companies of JNJ. Dr. Raju joined Centocor Inc in 2004 which became Janssen R&D in 2011. At Centocor Dr. Raju has worked as an Assistant Director and then as a Research Fellow. Prior to Centocor, Dr. Raju has spent more than 5 years at Genentech and little more than a year at Fibrogen. Dr. Raju’s research interest is to explore structure-function relationship of antibody glycosylation and glycoprotein therapeutics. Dr. Raju has more than 18 years of experience in the research and development of biotherapeutics including monoclonal antibodies and glycoproteins. Dr. Raju was involved in the development of leading cancer therapeutics such as Rituxan, Herceptin, Avastin and immunology therapeutics such as Remicade, Simponi etc. Dr. Raju has published more than 40 research articles, several reviews and book chapters. He is currently in the editorial board of mAbs, Analytical Biochemistry, BioProcess International and Drug Discovery and Development journals. Dr. Raju has been a member of ACS and Division of Carbohydrate for the last 25 years. He is also a member of ASBMB for the past 18 years.

Employment

  • Stealth Mode Biotech Head of Biologics
    2021 - Present
  • CHO Plus VP and Head
    2020 - 2021
  • Venn Therapeutics Head of R&D
    2017 - 2020
  • Medimmune Senior Director
    2016 - 2017
  • Janssen Research and Development Scientific Director
    2004 - 2016

Education

  • University of Mysore Ph.D.

Projects & Funding

Projects & funding information is unavailable.

Publications (10)